Abstract submission for ADI 2020 now open!

26 June 2019 – Abstract submission is now open for the 34th International Conference of Alzheimer's Disease International (ADI), to take place in Singapore in March 2020. [read more]

Novartis, Amgen and Banner Alzheimer's Institute remain committed after discontinuation of two Generation Program studies

11 July 2019 – Novartis, Amgen and Banner Alzheimer's Institute have announced the discontinuation of investigation of the BACE1 inhibitor CNP520 (umibecestat) in two Phase II/III studies. The decision followed the identification of worsening in some measures of cognitive function during a regular pre-planned review of unblinded data; the sponsors concluded that the potential benefit for participants in the studies did not outweigh the risk.

Dr. John Tsai, Head of Global Drug Development and Chief Medical Officer, said: [read more]

Dementia and healthy ageing given prominent focus at the G20

4 July 2019 – Dementia was specifically recognised as a global health priority by G20 leaders in the declaration of the Osaka Summit this weekend. ADI worked hard for this to happen and it will provide much needed global attention from G20 countries, as we continue to press governments to respond the healthcare challenges of dementia and to improve the lives of people with living dementia and their families. [read more]

Canadian government launches national plan to tackle dementia

17 June 2019 – The government of Canada today adopted a national plan on dementia. The plan is the 32nd to be adopted worldwide, and includes key targets for improving awareness, access to care, support and treatment, research and risk reduction of dementia by 2025. [read more]

Syndicate content